HIV patients respond well to Gilead's 4-drug combo in study

09/19/2011 | Bloomberg

Quad, an investigational four-drug cocktail by Gilead Sciences, achieved a 90% response rate among HIV patients in a Phase III trial, compared with 87% for those given Atripla, an approved treatment combining Gilead's two-in-one pill Truvada and Bristol-Myers Squibb's Sustiva. Gilead aims to file by year-end for FDA approval of Quad, said chief scientific officer Norbert Bischofberger.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID